Member Info for tomhuk2000

Well, this board takes the biscuit. As an investor who has a near TR1 share holding who bought in at 11p recently, all I can say is that we will just have to see where the company and share price stand in the coming weeks and months.

If the company haven’t started to monetise Parsortix effectively and the funds (due to last until Q2 2025 as per recent RNS) dry up, then I’ll happily hold my hands up and say I’ve invested my money badly.

However if this is a turnaround for AGL and the work they’ve done recently to make commercialisation more accessible/desirable (the reason I’ve bought in) then a few on this board should really take a long hard look in the mirror and consider whether their posts on here have encouraged potential investors to stay clear and miss this opportunity in making money and supporting a cancer research focussed company.

I can’t stand idle ramping, but agenda driven deramping/shorting (particularly of a cancer related stock) is a morally bankrupt endeavour l… naming no names TwoGood et al.

It’s been a great start to 2024… Long may it continue for investors new/longterm and for benefit cancer patients out there.

TwoGood2Die??? Please elaborate. We already have FDA approval, CE mark, UK mark, 26 patents, approved sales platforms in USA, China, UK, Europe, Japan and Australasia and the list goes on.

You state the RNS’d success percentages aren’t good enough for diagnostic purposes when you know (and criticised/posted last week) that this tech isn’t used in direct patient diagnostics and is designed and marketed for the cancer research market.

WARNING TO ALL NEW INVESTORS: DO YOUR OWN RESEARCH AND BE WARY OF AGENDA DRIVEN POSTERS LIKE THIS GUY.

START WITH THIS LINK:

https://x.com/redditdeluxe/status/1735222212985082111?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

As you’ll see if you look back over the past few weeks of posts on this board, there has been a concerted effort by TwoGood2Die to deramp this share.

He/She wouldn’t answer whether they were a current or former holder of AGL and their posts were poorly researched and lacking any credibility.

There’s usually a few options for this type of action: they’re shorting the company, or they’ve lost money here before and hold a grudge, or they are trying to drive the price down for a lower entry. (Or of course a more insidious agenda)

TwoGood2Die Certainly should be ashamed of himself. Mindless deramping with barely an whiff of sense/research/wit.

I wonder how many newbie investors he/she put off buying and subsequently missed this recent rise and overall opportunity.

Really rather shameful to be deramping/shorting a company specialising in cancer research. Report, block and move on.

"An impressive start to 2024 for #AGL

Here CEO Andrew Newland highlights the revenue potential from yesterday's pilot study announcement with multibillion-dollar pharmaceutical company Eisai

As previously stated: "A single contract could generate tens of millions in revenue"

https://x.com/RedditDeluxe/status/1742922848036090236?s=20

Interesting addition at the end of the RNS:

“ ANGLE is engaging with Illumina, leading KOLs and oncologists to seek their input and consideration of the benefits of the combined ctDNA / CTC-DNA approach giving a new and unique insight into cancer clonal evolution. The early stage responses have been encouraging.”

Bantham, yeah we can only wait and see where this will end up. In my opinion this news tees up deals to start flowing in. But we can but wait.

FeverTree, understand your caution. But with ovarian/prostate study’s due and hopefully new deals on the horizon you could well see your previous paper losses recouped.

A Great RNS here and one that tees up ANGLE to make 2024 rather spectacular.

As a “shareholder” you must be delighted FeverTreeMan?

And Bantham, TwoGoodToDie et al you must be very pleased that AGL’s service offering is one that will benefit the advancement of cancer treatment worldwide?

“ Announcing new contract with large pharma company, Eisai Inc. A pilot study using ANGLE’s Portrait HER2 test will assess Eisai’s novel therapeutic for breast cancer, BB-1701. This opportunity could open doors for future large-scale opportunities with Eisai Inc.”

https://x.com/parsortix/status/1742574173837234262?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

#AGL are attending the Proactive One2One Investor Forum specialising in the biomedical/pharmaceutical sectors on 11th January 2024

One would like to think they might have some updates in store prior (contract wins or 3rd party molecular results perhaps?)

@proactive_UK @Parsortix

Hi Bantham,

In your previous posts you've seemed quite open minded and balanced. But this post seems a little one sided don’t you think?

Pre Xmas critics were hammering Newland for not delivering deals. Now he delivers a deal, albeit a pilot study that if successful could lead to further business with this client. A client who is both a “large” and “global” pharmaceutical company. (Check the about/history section of their website).

Then to credit TwoGood with loving how he sums this news up… An obvious moron/troll with nothing to add but snide one-liners. Again seems a little one sided.

Let’s see how this (and hopefully other deals) progress shall we?

Happy New Year FeverTree

I thought as an existing holder, you’d be a bit happier about today’s news.

In November’s presentation, the CEO describes this very dynamic of pilot/preliminary studies ending up leading to much bigger deals with the pharmaceutical companies in question.

As you’ve stated in the past, deals with big pharmaceutical companies are complicated things and any enterprise worth it’s salt would want to trial the product before doing a bigger all encompassing deal.

As a longterm holder yourself it might be prudent to see how the pilot study goes before slating the company in which you’ve invested. (Better chance of seeing a return on your position that way surely?)

Also the key takeaway from the RNS is that it’s a $250,000 PILOT study and…

“Success in the pilot study offers the potential for multiple large scale follow-up studies.”

“Strong start to 2024 for #AGL delivering on its promises with a contract win with large Pharma company EISAI INC.

Success in the $250,000 pilot study offers the potential for multiple large scale follow-up studies.”

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

https://x.com/redditdeluxe/status/1742090247104536937?s=46&t=IHEn1TE0c7FNFBktt6H8XQ

Or a New Year’s resolution to a big commercial deal across the line.

Hi FeverTree,

I mean this with the greatest of respect, but it seems utterly illogical to continue to slate a company you are invested in on a public forum. Unless of course you’re not actually invested?

If I were this unhappy with my investment, I would sell up and move on rather than discourage buyers and therefore perpetuate your losses.

I would agree with you, hence my recent investment. Longterm investor frustrations come from the lack of commercial deals since the FDA approval etc. But, as I stated earlier in the week, efforts have been made to make the service offering more commercially accessible. Looking forward to the coming weeks and months.

Hi FeverTree and Bantham,

Thought you might be interested, I have been in touch with AGL via email regarding director buying and how much the BOD are holding. He replied:

One such source of information is

Angle Directors Deals. AGL Directors Share Dealings. (lse.co.uk)

“However, for ease the Shareholdings of the Executive Directors is:

Andrew Newland 7,378,512

Ian Griffiths 1,241,332

The Non-executive Directors typically have either a small holding (Brian Howlett 10,000 shares) or none at all given the nature of their independent role.”

So currently based in todays prices Approx:

CEO = (Current Value: £795k)

CFO = (Current Value: £133.5k)

i agree in most parts with both of you.

what i think we can all agree on is the fact that agl has very much been a case of good science/bad business.

i certainly think that there was a misjudgement by the bod about the ease of marketability of their service. this was probably due to a combination of overoptimism, a lack of business nouse, not a great understanding of the market and, a certain degree of arrogance.

the technology however, is really rather good and since the 80p raise i think that the bod have had to give themselves a kick up the **** to put certain things in place to win these commercial deals, and they’ve realised that the tech isn’t enough to stand up on its own, they need a more business minded approach.

let’s hope it works for them, and for us!

Very encouraging to see a bit more volume after a few dead days. 👍🏻

Fevertree,

My comment on being invested in small caps wasn’t meant to be in any way offensive. It’s just there are so many company’s out there on AIM where the directors have zero holdings in the company that I assumed you only invested in larger or more established stocks.

Personally, as an investor, I don’t need to see the entire board buying. As long as the CEO and CFO have reasonable holdings then I’m happy. (And they do)